A medical device can be designated for the De Novo pathway when it offers novel technology with a reasonable assurance of safety and effectiveness.

View offers 2D and 3D visualisation, along with AI-based tools, to assist in clinical decision making.

View streamlines imaging analysis and visualization by using a suite of AI-enabled tools intended to aid clinical decision making.

GE HealthCare Technologies Inc. GEHC recently announced that the FDA has granted 510(k) clearance for View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace. For ...

As noted in Chapter 1, the committee was charged by the Food and Drug Administration (FDA) to review the 510(k) clearance process and answer two principal questions: Does the current 510(k) clearance ...

The Millipede88 aspiration catheter. [Image courtesy of Perfuze] Perfuze announced today that it received FDA 510(k) ...

Thursday, March 19, 2026 at 4:30 p.m. ET Chief Executive Officer — Steven Foster Chief Financial Officer — Kevin Williamson Need a quote from a Motley Fool analyst? Email pr@fool.com Revenue -- $1.5 ...

Moby summary of Tenon Medical, Inc.'s Q4 2025 earnings call ...

Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half ...

Q4 2025 Earnings Call March 19, 2026 4:30 PM EDTCompany ParticipantsSteven Foster - CEO, President & DirectorKevin ...

Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half ...

Tenon Medical, Inc. (NASDAQ:TNON) Q4 2025 Earnings Call Transcript March 19, 2026 Tenon Medical, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.36. Operator: Greetings ...